Effect of Daretozumab Combined with P-CTD Chemotherapy Regimen on Bone Metabolism Indicators and Immune Function in Patients with Multiple Myeloma

Wei Min; Zhu Yan

doi:10.3969/j.issn.1004-5775.2025.17.010

Abstract：Objective:To explore the effects of Daretozumab(DARA)combined with P-CTD chemotherapy on bone metabolism indicators and immune function in patients with multiple myeloma(MM).Methods:92 MM patients admitted to the hospital from October 2022 to October 2023 were selected,and all patients were divided into two groups using a random number table method.The control group was treated with P-CTD chemotherapy regimen,while the observation group was treated with DARA combined with P-CTD chemotherapy regimen.The clinical efficacy,bone metabolism indicators,and immune function were compared between two groups.The adverse reactions of the two groups were calculated.Results:After treatment,the disease control rate(DCR)of the observation group was significantly higher than that of the control group(χ2=4.449,P<0.05).After treatment,the levels of alkaline phosphatase(ALP)and osteocalcin(BGP)in both groups were all higher than before treatment,while the C-terminal peptide of type I collagen(CTX-Ⅰ)was lower than before treatment.In addition,the ALP and BGP in the observation group were higher than those in the control group,and CTX-Ⅰ was lower than those in the control group(t=7.194,5.535,9.886;P<0.05).After treatment,the levels of CD3+,CD4+and CD4+/CD8+in both groups were higher than before treatment,and CD8+was lower than before treatment.In addition,the levels of CD3+,CD4+and CD4+/CD8+in the observation group were higher than those in the control group,and CD8+was lower than those in the control group(t=4.826,6.103,11.614,7.270;P<0.05).There was no significant difference in the total adverse reaction rates between the two groups(χ2=1.781,P>0.05).Conclusion:The combination of DARA and P-CTD chemotherapy is effective in treating MM patients.It can improve bone metabolism indicators,regulate immune function,and not significantly increase adverse reactions.